KALA BIO Announces Chief Executive Officer Transition

Core Viewpoint - KALA BIO, Inc. announces the resignation of CEO Mark Iwicki and the appointment of Todd Bazemore as interim CEO, effective immediately, while Iwicki will remain as Chair of the Board [1][2] Company Overview - KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and severe eye diseases [3] - The company utilizes its proprietary mesenchymal stem cell secretome (MSC-S) platform for its investigational therapies [3] Leadership Transition - Mark Iwicki has been with KALA and is proud of the work done utilizing the MSC-S platform, particularly regarding the lead product candidate KPI-012 for treating persistent corneal epithelial defect (PCED) [2] - Todd Bazemore, who has over 30 years of experience in the pharmaceutical industry, has been with KALA since November 2017 and will lead the company during this transition [2][3] Product Development - KALA's lead product candidate, KPI-012, is in clinical development for PCED and has received Orphan Drug and Fast Track designations from the U.S. FDA [3] - The company is also exploring the potential of KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases, as well as preclinical studies for retinal degenerative diseases [3]